Results 141 to 150 of about 580,274 (238)

Deciphering the transcriptomic landscape of early HR+/HER2− breast cancer in very young women

Cancer Communications, EarlyView.
Iris Garrido‐Cano, Marta Tapia, Juan Carbonell, Carlos Peña, Sandra Torres‐Ruiz, Anna Ágreda‐Roca, Ana Lameirinhas, Cristina Tebar, Octavio Burgués, Cristina Hernando, Ana Lluch, Fara Brasó‐Maristany, Aleix Prat, Begoña Bermejo, María Teresa Martínez, Juan Miguel Cejalvo   +15 more
wiley   +1 more source

First‐in‐Human Phase 1 Study to Evaluate the Clinical Pharmacology Properties of RBN‐3143, a Novel Inhibitor of Mono‐Adenosine Diphosphate Ribosyltransferase‐PARP14

Clinical Pharmacology in Drug Development, EarlyView.
Abstract RBN‐3143 is an inhibitor of PARP14 in development for inflammatory diseases. Multiple assessments were conducted to evaluate the clinical pharmacology properties of RBN‐3134. A randomized, double‐blind, placebo‐controlled study assigned healthy volunteers (HVs) to single ascending doses (SADs) (25‐1000 mg) or multiple ascending doses (MADs ...
Thomas M. Polasek, Alexandra Cole, Viviana Bozón, Erika Manyak, Jonathan Novak, Barbara Yang, Briohny A. Johnston, Sudha Parasuraman, Kushal J. Paneliya, Virna Schuck   +9 more
wiley   +1 more source

Inpatient's, therapist's and staff's expectations regarding treatment and their effects on placebo response in the psychiatric ward - results from an add-on oxytocin RCT. [PDF]

Psychopharmacology (Berl)
Nitzan U, Grossman-Girron A, Sedoff O, Maoz H, Arad O, Tilbor E, Dror C, Bitan DT.   +7 more
europepmc   +1 more source

A Randomized Thorough QT Trial Using Concentration‐QT Analysis to Evaluate the Effects of Centanafadine on Cardiac Repolarization

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Centanafadine is a norepinephrine/dopamine/serotonin reuptake inhibitor in development for treatment of attention‐deficit/hyperactivity disorder. This double‐blind, placebo‐ and moxifloxacin‐controlled, 3‐period crossover trial evaluated the effects of centanafadine (EB‐1020) and its metabolite (EB‐10601) on cardiac repolarization in 30 ...
Osman S. Turkoglu, Xiaofeng Wang, Jennifer Repella‐Gordon, Susan E. Shoaf   +3 more
wiley   +1 more source

Report of similar placebo response in one internet versus onsite randomised controlled trials from the literature. [PDF]

Osteoarthr Cartil Open
Ooghe A, Liu X, Robbins S, Eyles JP, Deveza LA, Branders S, Clermont F, Pereira A, Hunter DJ.   +8 more
europepmc   +1 more source

Ascites of patients with solid tumors shows distinct inflammatory patterns

Cancer Communications, EarlyView.
Julia M. Berger, Martin Korpan, Carina Zierfuss, Katharina Syböck, Erwin Tomasich, Andreas Kienzle, Maria Koenig, Markus Kleinberger, Lynn Gottmann, Birgit Fendl, Cihan Ay, Johannes Pammer, Catharina Müller, Rudolf Oehler, Lorenz Balcar, Thomas Reiberger, Elisabeth S. Bergen, Barbara Niederdorfer, Matthias Preusser, Anna S. Berghoff   +19 more
wiley   +1 more source

A 2‐Part, Open‐Label, Phase 1 Bioequivalence and Food‐Effect Study of Ubrogepant in Healthy Adult Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract This Phase 1 study of ubrogepant was conducted to establish the bioequivalence (BE) of the 50‐ and 100‐mg to‐be‐marketed (TBM) tablet formulations with the clinical trial (CT) 100‐mg tablet formulation and evaluate the food effect on the bioavailability of the 100‐mg TBM tablet. This 2‐part study enrolled healthy participants aged 18‐45 years.
Ramesh Boinpally, Joel M. Trugman
wiley   +1 more source

Placebo Response and Media Attention in Randomized Clinical Trials Assessing Cannabis-Based Therapies for Pain: A Systematic Review and Meta-analysis.

JAMA Netw Open, 2022
Gedin F, Blomé S, Pontén M, Lalouni M, Fust J, Raquette A, Vadenmark Lundquist V, Thompson WH, Jensen K.   +8 more
europepmc   +1 more source

Placebo response and effect in randomized clinical trials: meta-research with focus on contextual effects. [PDF]

Trials, 2021
Hafliðadóttir SH, Juhl CB, Nielsen SM, Henriksen M, Harris IA, Bliddal H, Christensen R.   +6 more
europepmc   +1 more source

Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost

Clinical Pharmacology &Therapeutics, EarlyView.
Model‐informed drug development (MIDD) integrates data to quantify benefit/risk informing objective drug discovery and development decisions. An additional critical benefit of MIDD is postulated to be improvement in trial and program efficiencies. While the application of MIDD has grown, there have been no clear examples across programs to demonstrate ...
Vaishali Sahasrabudhe, Timothy Nicholas, Gianluca Nucci, Cynthia J Musante, Brian Corrigan   +4 more
wiley   +1 more source